The novel ocular drug delivery devices market is projected to grow at a CAGR of 15%, till 2030, claims Roots Analysis
LONDON, ENGLAND, UNITED KINGDOM, October 12, 2021 /EINPresswire.com/ — The delivery of drugs in ocular regions is known to be considerably more challenging; several pharmaceutical companies are actively undertaking initiatives to identify novel approaches for safe and efficient administration of therapies to eyes
Over the years, a number of companies have developed several novel and advanced drug delivery devices, which are reported to be capable of addressing the known challenges in this domain. The anticipated growth in the patient population for such disorders is likely to increase demand for effective and patient centric ocular drug delivery devices.
To order this 200+ page report, which features 90+ figures and 115+ tables, please visit this https://www.rootsanalysis.com/reports/novel-ocular-drug-delivery-devices-market.html
Key Market Insights
Over 45 novel ocular drug delivery devices have either been approved or are being developed
Currently, 13% of such drug delivery devices are marketed, while majority (44%) of the systems are being evaluated in preclinical and discovery stages. Further, most (88%) of these devices are intended for the delivery of small molecule-based therapies.
Close to 80% of the novel ocular drug delivery devices in the pipeline are implants
Inserts and punctal plugs represent 10% of the development pipeline, each. Further, majority (60%) of such drug delivery devices are biodegradable. It is also worth mentioning that most (75%) of the ocular drug delivery device developers are based in North America, primarily in the US.
Clinical trials registered in this domain have increased at a CAGR of 29%, during 2018-2021
A number of clinical studies focused on the evaluation of novel drug delivery devices are currently ongoing worldwide. Of the total, close to 55% of the studies have already been completed, followed by 33% trials which are currently active and recruiting patients.
Over 1,145 patents related to novel ocular drug delivery devices have been granted / filed
There was significant increase in the number of patent applications filed over the last few years. Interestingly, more than 100 patents were filed / granted in 2020. Further, around 45% of the patents were filed in North America. It is worth highlighting that most of the patents were granted / filed for ocular implants.
Partnership activity within this domain has increased at a CAGR of 18%, between 2017 and 2021
Research and development agreements emerged as the most popular type of partnership model adopted by industry stakeholders, followed by product commercialization agreements (12%), product commercialization and development agreements (12%), and product distribution agreements (8%).
More than USD 3.5 billion has been invested by both private and public investors in this domain
It is important to mention that, between pre-2011 and 2021, majority of the funding amount was raised through secondary offerings (68%) and debt financing (20%). Further, most (93%) of the funding rounds were reported in the US.
North America and Europe are anticipated to capture over 88% of the market share, by 2030
The current market is driven by sales of novel ocular drug delivery devices designed to treat non-infectious uveitis (over 32%), followed by those targeting diabetic macular edema (22%) and glaucoma (13%). Further, ocular drug delivery inserts currently capture the dominant share (90%) of the market (in terms of sales-based revenues); this trend is unlikely to change in the foreseen future.
To request a sample copy / brochure of this report, please visit this
Key Questions Answered
Who are the leading novel ocular drug delivery device developers?
Which are the popular types of novel ocular drug delivery devices available in this market?
What are the key challenges faced by stakeholders engaged in this domain?
What types of partnership models are commonly being adopted by stakeholders in this industry?
Who are the key investors in this domain?
How is the intellectual property landscape in this field likely to evolve in the foreseen future?
What are the factors that are likely to influence the evolution of this market?
How is the current and future market opportunity likely to be distributed across key market segments?
The financial opportunity within the novel ocular drug delivery devices market has been analyzed across the following segments:
Type of Drug Delivery Device
Retinal vein occlusion
Postoperative ocular inflammation
Diabetic macular edema
Dry eye disease
Wet age-related macular degeneration
Neovascular age-related macular degeneration
Type of Product
Key Geographical Regions
Rest of the World
The report includes profiles of key players (listed below); each profile features an overview of the company, details related to its financials (if available), technology overview, product portfolios, recent developments and an informed future outlook.
Bausch & Lomb
For additional details, please visit
https://www.rootsanalysis.com/reports/novel-ocular-drug-delivery-devices-market.html or email firstname.lastname@example.org
You may also be interested in the following titles:
1. On-body Drug Delivery Devices Market, 2021-2030
2. Non-Viral Drug Delivery Systems Market, 2021-2030
3. Connected / Smart Drug Delivery Systems Market, 2021-2030
4. Diabetes Drug Delivery Devices Market, 2020-2030
5. Organ-based / Targeted Drug Delivery Devices Market, 2020-2030
+1 (415) 800 3415
+44 (122) 391 1091